Rhythm Pharmaceuticals to Present at Investor Conferences in September
September 09 2020 - 8:00AM
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage
biopharmaceutical company aimed at developing and commercializing
therapies for the treatment of rare genetic disorders of obesity,
today announced that company management will present at two
investor conferences in September:
Morgan Stanley 18th Annual Global Healthcare
Conference on Wednesday, September 16, 2020.
- David Meeker, M.D., Chair, President and Chief Executive
Officer, will participate in a fireside chat at 3:30 p.m. ET.
Cantor Virtual Global Healthcare Conference on
Thursday, September 17, 2020.
- Hunter Smith, Chief Financial Officer, will participate in a
fireside chat at 2:00 p.m. ET.
Live audio webcasts of both presentations will be available
under “Events & Presentations” in the Investor Relations
section of the Company’s website at www.rhythmtx.com. A replay of
the webcasts will be available on the Rhythm website for 30 days
following each presentation.
About Rhythm PharmaceuticalsRhythm is a
late-stage biopharmaceutical company focused on the development and
commercialization of therapies for the treatment of rare genetic
disorders of obesity. The Company is developing setmelanotide, its
investigational, melanocortin-4 receptor (MC4R) agonist, for the
treatment of severe obesity and hyperphagia associated with rare
genetic disorders of obesity. The U.S. Food and Drug Administration
(FDA) has accepted for filing Rhythm’s New Drug Application (NDA)
for setmelanotide for the treatment of pro-opiomelanocortin (POMC)
deficiency obesity and leptin receptor (LEPR) deficiency obesity
with Priority Review and a Prescription Drug User Fee Act (PDUFA)
goal date of November 27, 2020. Rhythm also submitted a
Marketing Authorization Application (MAA) for setmelanotide to
treat individuals living with POMC deficiency obesity or LEPR
deficiency obesity to the European Medicines Agency (EMA)
in June 2020. Rhythm is also evaluating setmelanotide for
reduction in hunger and body weight in a pivotal Phase 3 trial in
people living with Bardet-Biedl and Alström syndromes, with topline
data from this trial expected in the fourth quarter of 2020 or
early in the first quarter of 2021. The Company is leveraging the
Rhythm Engine -- comprised of its Phase 2 basket study, TEMPO
Registry, GO-ID genotyping study and Uncovering Rare Obesity
program -- to improve the understanding, diagnosis and potentially
the treatment of rare genetic disorders of obesity. For healthcare
professionals, visit www.UNcommonObesity.com for more
information. For patients and caregivers,
visit www.LEADforRareObesity.com for more information.
The company is based in Boston, MA.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation statements regarding the potential,
safety, efficacy, and regulatory and clinical progress of
setmelanotide, expectations regarding regulatory approval, the
anticipated timing for release of clinical trial data, and
participation in upcoming presentations and conferences. Statements
using words such as “expect”, “anticipate”, “believe”, “may”,
“will” and similar terms are also forward-looking statements.
These statements are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, the impact of our
management transition, our ability to enroll patients in clinical
trials, the design and outcome of clinical trials, the impact of
competition, the ability to achieve or obtain necessary regulatory
approvals, risks associated with data analysis and reporting, our
liquidity and expenses, the impact of the COVID-19 pandemic on our
business and operations, including our preclinical studies,
clinical trials and commercialization prospects, and general
economic conditions, and other important factors discussed under
the caption “Risk Factors” in our Quarterly Report on Form 10-Q for
the quarterly period ended June 30, 2020 and our other
filings with the Securities and Exchange Commission. Except as
required by law, we undertake no obligations to make any revisions
to the forward-looking statements contained in this release or to
update them to reflect events or circumstances occurring after the
date of this release, whether as a result of new information,
future developments or otherwise.
Corporate Contact:David ConnollyHead of
Investor Relations and Corporate CommunicationsRhythm
Pharmaceuticals, Inc.857-264-4280dconnolly@rhythmtx.com
Investor Contact:Hannah DeresiewiczStern
Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media Contact:Adam DaleyBerry & Company
Public Relations212-253-8881adaley@berrypr.com
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Apr 2023 to Apr 2024